| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EXEL | Common Stock | Tax liability | -$514K | -14.7K | -4.25% | $35.05 | 330K | Nov 15, 2024 | Direct | F1, F2 |
| transaction | EXEL | Common Stock | Sale | -$762K | -22.2K | -6.72% | $34.31 | 308K | Nov 18, 2024 | Direct | F2, F3, F4 |
| transaction | EXEL | Common Stock | Sale | -$667K | -19.4K | -6.29% | $34.41 | 289K | Nov 18, 2024 | Direct | F2, F5 |
| holding | EXEL | Common Stock | 23.5K | Nov 15, 2024 | By spouse | ||||||
| holding | EXEL | Common Stock | 10.6K | Nov 15, 2024 | By 401(k) | F6 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 6, 2023. |
| F2 | Includes 210,622 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. |
| F3 | The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. |
| F4 | Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.11 to $34.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. |
| F5 | Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.40 to $34.45. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4. |
| F6 | Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of November 14, 2024. |